US2020020247A1PendingUtilityA1

System and method for educating users, including responding to patterns

Assignee: DEXCOM INCPriority: May 7, 2015Filed: Sep 12, 2019Published: Jan 16, 2020
Est. expiryMay 7, 2035(~8.8 yrs left)· nominal 20-yr term from priority
A61B 5/1112G16H 20/60G16H 15/00A61B 5/7475A61B 5/4866G16H 50/50A61B 5/7435A61B 2562/0219A61B 5/1495A61B 5/1118A61B 5/14532A61B 5/0077A61B 5/14546A61B 5/0022A61B 5/742G16H 20/30A61B 5/4833G09B 19/0092A61B 5/486G16H 20/40A61B 5/4872G09B 19/00G16H 20/10G16H 50/30G16H 40/40G16H 50/20Y02A90/10
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are systems and methods using which users may learn and become familiar with the effects of various aspects of their lifestyle on their health, e.g., users may learn about how food and/or exercise affects their glucose level and other physiological parameters, as well as overall health. In some cases the user selects a program to try; in other cases, a computing environment embodying the system suggests programs to try, including on the basis of pattern recognition, i.e., by the computing environment determining how a user could improve a detected pattern in some way. In this way, users such as type II diabetics or even users who are only prediabetic or non-diabetic may learn healthy habits to benefit their health.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A method of monitoring a physiological characteristic or parameter involving a medicament, comprising:
 a. receiving data about a first medicament ingested by a user in a first regimen;   b. monitoring the presence or concentration of the first medicament in the user over a duration of time;   c. analyzing or evaluating the monitored presence or concentration of the first medicament against the first regimen over the duration of time to determine a physiological characteristic or parameter; and   d. displaying an output responsive to the analyzing or evaluating step.   
     
     
         22 . The method of  claim 21 , further comprising:
 a. monitoring and storing glucose concentration data of the user;   b. analyzing the monitored and stored glucose concentration data of the user;   c. evaluating the analyzed glucose concentration data of the user against the first regimen; and   d. displaying an output responsive to the evaluating step.   
     
     
         23 . The method of  claim 21 , further comprising correlating the monitored presence or concentration of the first medicament and the monitored and stored glucose concentration data of the user over the duration of time. 
     
     
         24 . The method of  claim 21 , wherein the physiological characteristic or parameter is a metabolic level. 
     
     
         25 . The method of  claim 21 , wherein the monitoring the presence or concentration includes identifying a signature of the first medicament. 
     
     
         26 . The method of  claim 21 , wherein the receiving data about a first medicament ingested by a user in a first regimen includes receiving data about a chemical that tracks ingestion of a medication, thereby tracking compliance with the first medication regimen. 
     
     
         27 . The method of  claim 26 , wherein the receiving data about a first medicament ingested by a user includes receiving data from a sensor that monitors or tracks the chemical. 
     
     
         28 . The method of  claim 26 , wherein the monitoring the presence or concentration includes identifying a signature of the chemical. 
     
     
         29 . The method of  claim 26 , further comprising:
 a. monitoring and storing glucose concentration data of the user, including receiving glucose concentration data from a continuous glucose monitor;   b. analyzing the monitored and stored glucose concentration data of the user, wherein the analyzing includes correlating the monitored presence or concentration of the first medicament and the monitored and stored glucose concentration data of the user over the duration of time; and   c. displaying an output responsive to the analyzing step.   
     
     
         30 . The method of  claim 21 , further comprising receiving data from a cloud connected source, the data pertaining to medicaments and/or regimens attempted by a plurality of other users, the plurality of other users determined by having similar demographics to the user, such that the displayed output is optimized for the user. 
     
     
         31 . The method of  claim 30 , the similar demographics including one or more similar demographic parameters selected from the group consisting of: age, ethnicity, weight, BMI, and type of diabetes. 
     
     
         32 . The method of  claim 21 , wherein the regimen includes data about a dosage of a respective medicament and the timing of ingestion of the respective medicament. 
     
     
         33 . The method of  claim 21 , further comprising monitoring other data about the user, and wherein the analyzing or evaluating steps, or both, are based on the glucose concentration data and the other data. 
     
     
         34 . The method of  claim 33 , wherein the other data includes activity data. 
     
     
         35 . The method of  claim 33 , wherein the other data include data about other analytes. 
     
     
         36 . The method of  claim 33 , wherein the other data include meal data. 
     
     
         37 . The method of  claim 36 , wherein the meal data is received from:
 a. a social network;   b. user entry;   c. a food app; or   d. photographic data.   
     
     
         38 . The method of  claim 21 , further comprising determining user compliance with the regimen. 
     
     
         39 . The method of  claim 21 , further comprising transmitting an indication of the output to a cloud connected entity, along with demographic data about the user.

Join the waitlist — get patent alerts

Track US2020020247A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.